Genentech Enters Type 1 Diabetes Space In Licensing Deal With Bayhill
This article was originally published in The Pink Sheet Daily
Executive Summary
Transaction offers an example of how Genentech and Roche’s business development arms will operate post-merger.
You may also be interested in...
Tysabri Returns, But Biogen Idec’s Oral MS Drug Buy May Mean More
Of the two recent events with major implications for Biogen Idec’s multiple sclerosis franchise, the less prominent – the acquisition of Fumapharm, its partner on the experimental oral MS therapeutic BG-12 – could, in the long run, be more significant than the re-approval of Tysabri.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.